BACKGROUND: Bovine lactoferrin addition to regimens of Helicobacter pylori treatment has been tried, with conflicting results. AIM: To assess the effect of bovine lactoferrin in addition to the anti-H. pylori treatment. METHODS: We enrolled 400 H. pylori-infected patients who were randomized into 4 equal groups: (A): proton-pump-based triple therapy (PpTT) for 2 weeks, (B): sequential therapy for 2 weeks, (C): proton-pump-based triple therapy plus bovine lactoferrin for 2 weeks, and (D): sequential therapy plus bovine lactoferrin for 2 weeks. RESULTS: In the per-protocol analysis, the success in groups A, B, C, and D were 70.3%, 82.8%, 85.6%, and 94.5%, respectively (P < .001). The treatment success rate for the sequential therapy plus bovine lactoferrin regimen was significantly higher than that with sequential therapy alone (94.5% vs. 82.8%, P = .013). The same applied for proton-pump-based triple therapy (85.6% vs. 70.3%, P = .014). The addition of bovine lactoferrin and the presence of endoscopic corpus gastritis were independent predictors for successful eradication of H. pylori. CONCLUSION: Bovine lactoferrin could hasten the effectiveness of the proton-pump-based triple therapy or sequential therapy for H. pylori eradication.
BACKGROUND: Bovine lactoferrin addition to regimens of Helicobacter pylori treatment has been tried, with conflicting results. AIM: To assess the effect of bovine lactoferrin in addition to the anti-H. pylori treatment. METHODS: We enrolled 400 H. pylori-infected patients who were randomized into 4 equal groups: (A): proton-pump-based triple therapy (PpTT) for 2 weeks, (B): sequential therapy for 2 weeks, (C): proton-pump-based triple therapy plus bovine lactoferrin for 2 weeks, and (D): sequential therapy plus bovine lactoferrin for 2 weeks. RESULTS: In the per-protocol analysis, the success in groups A, B, C, and D were 70.3%, 82.8%, 85.6%, and 94.5%, respectively (P < .001). The treatment success rate for the sequential therapy plus bovine lactoferrin regimen was significantly higher than that with sequential therapy alone (94.5% vs. 82.8%, P = .013). The same applied for proton-pump-based triple therapy (85.6% vs. 70.3%, P = .014). The addition of bovine lactoferrin and the presence of endoscopic corpus gastritis were independent predictors for successful eradication of H. pylori. CONCLUSION: Bovine lactoferrin could hasten the effectiveness of the proton-pump-based triple therapy or sequential therapy for H. pylori eradication.
Authors: A Leodolter; M Kulig; H Brasch; W Meyer-Sabellek; S N Willich; P Malfertheiner Journal: Aliment Pharmacol Ther Date: 2001-12 Impact factor: 8.171
Authors: S D Georgopoulos; S D Ladas; S Karatapanis; A Mentis; C Spiliadi; V Artikis; S A Raptis Journal: Dig Dis Sci Date: 2000-01 Impact factor: 3.199
Authors: F Di Mario; G Aragona; N Dal Bó; L Cavallaro; V Marcon; P Olivieri; E Benedetti; N Orzès; R Marin; G Tafner; F Chilovi; R De Bastiani; F Fedrizzi; M Franceschi; M H Salvat; F Monica; L Piazzi; F Valiante; U Vecchiati; G M Cavestro; G Comparato; V Iori; M Maino; G Leandro; A Pilotto; M Rugge; A Franzè Journal: Aliment Pharmacol Ther Date: 2006-04-15 Impact factor: 8.171
Authors: F Di Mario; G Aragona; N Dal Bò; G M Cavestro; L Cavallaro; V Iori; G Comparato; G Leandro; A Pilotto; A Franzè Journal: Dig Liver Dis Date: 2003-10 Impact factor: 4.088
Authors: Antonio Francesco Ciccaglione; Mara Di Giulio; Silvia Di Lodovico; Emanuela Di Campli; Luigina Cellini; Leonardo Marzio Journal: J Antimicrob Chemother Date: 2019-04-01 Impact factor: 5.790